Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1992-12-31
|
pubmed:abstractText |
After an initial placebo week, 37 depressed inpatients were treated with the fixed dose of 75 mg clomipramine b.d. A sparteine test was carried out during the placebo period and again during the second week of active therapy. Blood for drug assay was collected at the end of the inter-dose interval in the (morning) at weekly intervals. Clomipramine and four metabolites (desmethylclomipramine, didesmethylclomipramine, 8-hydroxyclomipramine, and 8-hydroxydesmethylclomipramine) in plasma were assayed by reversed phase HPLC. The clomipramine and desmethylclomipramine steady-state plasma levels varied by factors of 11 and 9, respectively, and the clomipramine/8-hydroxyclomipramine and desmethylclomipramine/8-hydroxydesmethylclomipramine ratios both varied by 7-fold. During the placebo week, 36 patients were phenotyped as extensive metabolizers (EM) (metabolic ratio, MR, 0.1-2.0), and one patient was phenotyped as a poor metabolizer (PM) (MR > 300). During clomipramine treatment, one patient changed phenotype from EM to PM (MR = 140). In the EM, the median of the MR increased from 0.4 to 2.3. There was a statistically significant correlation between the MR before and during clomipramine treatment, even when the PM was excluded. Neither the steady-state plasma clomipramine levels nor the clomipramine/desmethylclomipramine ratios showed a significant correlation with the MR. In contrast, the desmethylclomipramine and didesmethylclomipramine steady-state levels and the desmethylclomipramine/8-hydroxydesmethylclomipramine and clomipramine/8-hydroxyclomipramine ratios showed a significant positive correlation with the MR. The PM had the highest steady-state plasma desmethylclomipramine level and the highest desmethylclomipramine/8-hydroxydesmethylclomipramine ratio. These correlation coefficients (rs) were generally increased when the correlation analyses were based on the MR obtained during clomipramine treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/8-hydroxyclomipramine,
http://linkedlifedata.com/resource/pubmed/chemical/Clomipramine,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 Enzyme System,
http://linkedlifedata.com/resource/pubmed/chemical/Debrisoquin,
http://linkedlifedata.com/resource/pubmed/chemical/Sparteine,
http://linkedlifedata.com/resource/pubmed/chemical/desmethylclomipramine
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0031-6970
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
43
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
405-11
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1451721-Adult,
pubmed-meshheading:1451721-Aged,
pubmed-meshheading:1451721-Clomipramine,
pubmed-meshheading:1451721-Cytochrome P-450 Enzyme System,
pubmed-meshheading:1451721-Debrisoquin,
pubmed-meshheading:1451721-Depression,
pubmed-meshheading:1451721-Female,
pubmed-meshheading:1451721-Humans,
pubmed-meshheading:1451721-Male,
pubmed-meshheading:1451721-Middle Aged,
pubmed-meshheading:1451721-Oxidation-Reduction,
pubmed-meshheading:1451721-Phenotype,
pubmed-meshheading:1451721-Polymorphism, Genetic,
pubmed-meshheading:1451721-Sparteine
|
pubmed:year |
1992
|
pubmed:articleTitle |
Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group.
|
pubmed:affiliation |
Department of Clinical Pharmacology, Odense University, Denmark.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|